- Active not recruitingPHASE3
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
This study is testing a new injection, litifilimab, for adults with active lupus (SLE) who are already on standard treatments. Researchers want to see if it improves lupus symptoms and is safe over 52 weeks.
For: Lupus Erythematosus, SystemicUnited States · Argentina · Belgium - RecruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
For: Subacute Cutaneous Lupus Erythematosus · Chronic Cutaneous Lupus ErythematosusUnited States · Argentina · Belgium - Enrolling by invitationPHASE3
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
This study looks at the long-term safety and effects of a new drug, litifilimab, for adults with lupus. It's for people who were in earlier studies of the drug and aims to see if it helps manage symptoms and is safe over a longer period.
For: Systemic Lupus Erythematosus (SLE)United States · Argentina · Belgium